Amanote Research
Register
Sign In
BLU-667 Targets RET-Altered Cancers
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-050
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 15, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Targeting RET-driven Cancers: Lessons From Evolving Preclinical and Clinical Landscapes
Nature Reviews Clinical Oncology
Oncology
MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers
Canadian Journal of Gastroenterology and Hepatology
Medicine
Hepatology
Gastroenterology
Altered Sarcoplasmic Reticulum Calcium Cycling—targets for Heart Failure Therapy
Nature Reviews Cardiology
Cardiovascular Medicine
Cardiology
DB2 With BLU Acceleration
Proceedings of the VLDB Endowment
Computer Science
Performance Oriented Packaging Testing of the BLU-91/B Antitank Mine and the BLU-92/B Antipersonnel Mine
Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET -Rearranged Lung Cancers
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
From Smoking to Cancers: Novel Targets to Neuronal Nicotinic Acetylcholine Receptors
Journal of Oncology
Oncology
Consequences of Altered Isoprenylation Targets on A-Factor Export and Bioactivity.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
